<unk>  of the left axilla. CT, coronal reconstruction Treatment is primarily surgical, with chemotherapy and radiation therapy used if clear resection margins are not acquired. Surgical treatment The type of surgical treatment chosen is dependent on the location of the<unk>  occurrence and possible size. Mohs surgery Mohs Micrographic Surgery (MMS) has a high cure rate and lowers the recurrence reduction of<unk>  if negative resection margins are achieved. Wide local excision WLE was the gold standard for treating<unk>  but is currently under reevaluation. Presently in the United States, WLE may be suggested after the recurrence of MMS. Larger resection margins are suggested for WLE than MMS. Recurrence rate with WLE is about 8.5% with a lower recurrence rate related to wider excision. Resection margin<unk>  characteristic features are its capacity to invade surrounding tissues, to a considerable distance from the central focus of the tumor in a "tentacle-like" fashion. This fact, coupled with diagnostic delay, may lead to inadequate initial resection. Inadequate initial treatment results in larger, deeper recurrent lesions, but these can be managed by appropriate wide excision. Radiation therapy<unk>  is a radioresponsive tumor, radiation therapy (RT) is not used as the first choice for treatment. Conservative resection through MMS or WLE is attempted first. If clear margins are not achieved RT, or Chemotherapy is recommended. Chemotherapy<unk>  was previously regarded and nonresponsive to standard chemotherapy. In 2006 the US FDA approved (imatinib mesylate) for the treatment of<unk> . As is true for all medicinal drugs that have a name that ends in "ib," imatinib is a small molecular pathway inhibitor; imatinib inhibits tyrosine kinase. It may be able to induce tumor regression in patients with recurrent<unk> , unresectable<unk> , or metastatic<unk> . There is clinical evidence that imatinib, which inhibits PDGF-receptors, may be effective for tumors positive for the t(17;22) translocation. It is suggested that imatinib may be a treatment for challenging, locally advanced disease and in the rare metastatic cases It was approved for use by adult patients with unresectable, recurrent and/or metastatic<unk>  <unk> .
Dermatofibrosarcoma protuberans
Dermatofibroma
Elastofibroma dorsi
Angiokeratoma
Lymphangioma circumscriptum
Chondroid syringoma
Pseudomelanoma
Sarcoma botryoides